

The Opportunity and Challenge of Biomanufacturing

Innovative biotherapeutics are transforming the lives of patients around the world every day. They offer a powerful defense against serious medical conditions such as cancer, diabetes, and rheumatoid arthritis. Manufacturers are challenged to develop and deliver these products in a dynamic, everchanging environment where speed and efficiency are critical.

While monoclonal antibodies have proven themselves for many years as a therapeutic modality for a wide range of human diseases, a growing focus on drugs for smaller patient populations has created a tremendous amount of change in the biopharma industry. Investing in a large facility for a single product is no longer a sustainable business model. Instead, pharma companies are looking to collaborate with CDMOs to augment their capacity and expertise, refine their processes, and ultimately shorten their time to market.

Choosing to work with a CDMO creates a new set of factors to consider. This is designed to help you determine if working with a CDMO is right for you – and if so, you'll discover the best practices that make working with a CDMO as efficient as possible. You'll answer questions such as:

- Do we have the right in-house resources to do this work on our own?
- If we decide to build our own facility, can a CDMO help us to keep our molecule on track until the new facility is online?
- What do we have to gain by working with a CDMO? And what are the risks?
- What can I do to ensure a smooth tech transfer to the CDMO?
- What will the CDMO do to protect my intellectual property?

Companies that can adapt to this new paradigm of flexibility and agility in biomanufacturing will be the ones who succeed as the industry continues to evolve. And for every success, there's another group of patients in the world whose lives will be dramatically improved.

Source

Accelerate your pipeline with CDMO collaboration.